SCYX News and Press, SCYNEXIS Inc. From 03/28/22

ASO, BGRY, CONN, DPRO, EH, ESLT, HUMA, KALA, LODE, LOVE, MKC, SCYX, UXIN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will announce fourth quarter and full year 2021 financial results and p...

JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it has been named to Fast Company ’s annual ...

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash. SCYX's Brexafemme is clinically de-risked and targets an attractive fungal infection space. Eve...

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conference...

SCYNEXIS (NASDAQ:SCYX) announced on Thursday that the company’s Phase 3 CANDLE study for the fungicidal agent, ibrexafungerp, met the primary and key secondary endpoints with statistical significance in the prevention of recurrent vulvovaginal candidiasis (rVVC), also known as vaginal ...

Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints. SCYNEXIS will submit a supplemental New Drug Application (sNDA) for BREXAFEMM...

SCYNEXIS (NASDAQ:SCYX) granted stock options and Restricted Stock Units to five new employees; grants consists of 41K shares exercisable at $4.9/share. Each option has a 10-year term, with one-fourth of the shares subject to the option vesting on the 1-year anniversary of the employee&#x...

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executiv...

JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 3.37 million shares ...